These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 38952127)

  • 1. Increased Risk of End-Stage Kidney Disease in Patients with Chronic Kidney Disease and Heart Failure with Reduced Ejection Fraction.
    Al-Chalabi S; Poulose M; Rengarajan S; Kalra PR; Green D; Chinnadurai R; Sinha S; Kalra PA
    Cardiorenal Med; 2024; 14(1):397-406. PubMed ID: 38952127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk Factors and Outcomes Associated With Heart Failure With Preserved and Reduced Ejection Fraction in People With Chronic Kidney Disease.
    Bansal N; Zelnick LR; Scherzer R; Estrella M; Shlipak MG
    Circ Heart Fail; 2024 May; 17(5):e011173. PubMed ID: 38742428
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Associations with and prognostic impact of chronic kidney disease in heart failure with preserved, mid-range, and reduced ejection fraction.
    Löfman I; Szummer K; Dahlström U; Jernberg T; Lund LH
    Eur J Heart Fail; 2017 Dec; 19(12):1606-1614. PubMed ID: 28371075
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The association of chronic kidney disease and microalbuminuria with heart failure with preserved vs. reduced ejection fraction.
    Nayor M; Larson MG; Wang N; Santhanakrishnan R; Lee DS; Tsao CW; Cheng S; Benjamin EJ; Vasan RS; Levy D; Fox CS; Ho JE
    Eur J Heart Fail; 2017 May; 19(5):615-623. PubMed ID: 28217978
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association Between β-Blocker Use and Mortality/Morbidity in Patients With Heart Failure With Reduced, Midrange, and Preserved Ejection Fraction and Advanced Chronic Kidney Disease.
    Fu EL; Uijl A; Dekker FW; Lund LH; Savarese G; Carrero JJ
    Circ Heart Fail; 2020 Nov; 13(11):e007180. PubMed ID: 33070637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardio-renal-metabolic syndrome: clinical features and dapagliflozin eligibility in a real-world heart failure cohort.
    Beles M; Masuy I; Verstreken S; Bartunek J; Dierckx R; Heggermont W; Oeste C; De Boeck M; Fovel I; Maris M; Vermeulen Z; Vanderheyden M
    ESC Heart Fail; 2023 Aug; 10(4):2269-2280. PubMed ID: 37095712
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and proteomic profiles of chronic kidney disease in heart failure with reduced and preserved ejection fraction.
    Voordes GHD; Voors AA; Hoegl A; Madsen CT; van Essen BJ; Ouwerkerk W; Tromp J; de la Rambelje MA; Grønborg M; Refsgaard JC; Lang CC; Barascuk-Michaelsen N; Damman K
    Int J Cardiol; 2024 Dec; 417():132580. PubMed ID: 39306286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sacubitril/valsartan improves all-cause mortality in heart failure patients with reduced ejection fraction and chronic kidney disease.
    Lee WC; Liao TW; Chen TY; Fang HY; Fang YN; Chen HC; Lin YS; Chang SH; Chen MC
    Cardiovasc Drugs Ther; 2024 Jun; 38(3):505-515. PubMed ID: 36609948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Feature and impact of guideline-directed medication prescriptions for heart failure with reduced ejection fraction accompanied by chronic kidney disease.
    Chen YL; Hang CL; Su CH; Wu PJ; Chen HC; Fang HY; Fang YN; Cheng CI; Fu M; Chen SM
    Int J Med Sci; 2021; 18(12):2570-2580. PubMed ID: 34104088
    [No Abstract]   [Full Text] [Related]  

  • 10. Renal tubular damage and clinical outcome in heart failure with preserved ejection fraction and chronic kidney disease.
    Otaki Y; Watanabe T; Shimizu M; Tachibana S; Sato J; Kobayashi Y; Saito Y; Aono T; Tamura H; Kato S; Nishiyama S; Takahashi H; Arimoto T; Watanabe M
    ESC Heart Fail; 2023 Aug; 10(4):2458-2468. PubMed ID: 37264723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic kidney disease and outcomes in heart failure with preserved versus reduced ejection fraction: the Cardiovascular Research Network PRESERVE Study.
    Smith DH; Thorp ML; Gurwitz JH; McManus DD; Goldberg RJ; Allen LA; Hsu G; Sung SH; Magid DJ; Go AS
    Circ Cardiovasc Qual Outcomes; 2013 May; 6(3):333-42. PubMed ID: 23685625
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retrospective analysis of SGLT2 inhibitors in heart failure with preserved ejection fraction.
    Clemmer JS; Ward TJ; Lirette ST
    ESC Heart Fail; 2023 Jun; 10(3):2010-2018. PubMed ID: 37042079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-cardiac comorbidities in heart failure with reduced, mid-range and preserved ejection fraction.
    Streng KW; Nauta JF; Hillege HL; Anker SD; Cleland JG; Dickstein K; Filippatos G; Lang CC; Metra M; Ng LL; Ponikowski P; Samani NJ; van Veldhuisen DJ; Zwinderman AH; Zannad F; Damman K; van der Meer P; Voors AA
    Int J Cardiol; 2018 Nov; 271():132-139. PubMed ID: 30482453
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.
    House AA; Wanner C; Sarnak MJ; Piña IL; McIntyre CW; Komenda P; Kasiske BL; Deswal A; deFilippi CR; Cleland JGF; Anker SD; Herzog CA; Cheung M; Wheeler DC; Winkelmayer WC; McCullough PA;
    Kidney Int; 2019 Jun; 95(6):1304-1317. PubMed ID: 31053387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence and Prognostic Implications of Longitudinal Ejection Fraction Change in Heart Failure.
    Savarese G; Vedin O; D'Amario D; Uijl A; Dahlström U; Rosano G; Lam CSP; Lund LH
    JACC Heart Fail; 2019 Apr; 7(4):306-317. PubMed ID: 30852236
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of continuing mineralocorticoid receptor antagonist treatment in patients with heart failure with reduced ejection fraction and severe kidney disease: Data from Swedish Heart Failure Registry.
    Guidetti F; Lund LH; Benson L; Hage C; Musella F; Stolfo D; Mol PGM; Flammer AJ; Ruschitzka F; Dahlstrom U; Rosano GMC; Braun OÖ; Savarese G
    Eur J Heart Fail; 2023 Dec; 25(12):2164-2173. PubMed ID: 37795642
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heart failure with anemia: novel findings on the roles of renal disease, interleukins, and specific left ventricular remodeling processes.
    O'Meara E; Rouleau JL; White M; Roy K; Blondeau L; Ducharme A; Neagoe PE; Sirois MG; Lavoie J; Racine N; Liszkowski M; Madore F; Tardif JC; de Denus S;
    Circ Heart Fail; 2014 Sep; 7(5):773-81. PubMed ID: 25027873
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mortality and Renal Outcomes Are Impacted by Obesity in Cardiorenal Metabolic Disease but Not in People with Concomitant Diabetes Mellitus.
    Al-Chalabi S; Chinnadurai R; Kalra PA; Sinha S
    Cardiorenal Med; 2024; 14(1):23-33. PubMed ID: 38160668
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sex differences in Cardiorenal Syndrome: Insights from CARDIOREN Registry.
    Cobo Marcos M; de la Espriella R; Gayán Ordás J; Zegrí I; Pomares A; Llácer P; Fort A; Rodríguez Chavarri A; Méndez A; Blázquez Z; Caravaca Pérez P; Rubio Gracia J; Recio-Mayoral A; García Pinilla JM; Soler MJ; Garrido González R; Górriz JL; González Rico M; Castro A; Núñez J
    Curr Heart Fail Rep; 2023 Jun; 20(3):157-167. PubMed ID: 37222949
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of Sarcopenia in Chronic Heart Failure and Modulating Role of Chronic Kidney Disease.
    Formiga F; Moreno-Gónzalez R; Corsonello A; Mattace-Raso F; Carlsson AC; Ärnlöv J; Kostka J; Freiberger E; Roller-Wirnsberger R; Tap L; Sołtysik BK; Artzi-Medvedik R; Kob R; Yehoshua I; Wirnsberger GH; Fabbietti P; Lattanzio F; Chivite D;
    Gerontology; 2024; 70(5):507-516. PubMed ID: 38320538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.